SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tnsaf6/30/2009 12:24:52 PM
  Read Replies (1) of 7143
 
Jury awards Centocor $1.7B in patent case against Abbott

Centocor Ortho Biotech Inc. said late Monday that a federal jury has awarded the company $1.67 billion in a patent infringement case against Abbott Laboratories.

Horsham, Pa.-based Centocor, a division of Johnson & Johnson (NYSE:JNJ), makes the blockbuster rheumatoid arthritis treatment Remicade, and had sued Abbott over Abbott’s arthritis drug, Humira. Both are so-called anti-TNF arthritis treatments.

Horsham, Pa.-based Centocor said it is the exclusive licensee of the patent, which is co-owned by New York University.

Centocor President Kim Taylor said “the jury recognized our valuable intellectual property, finding our patent both valid and infringed. We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatment for patients with a number of immune mediated inflammatory diseases.”

An Abbott representative could not be immediately reached for comment.

Reports said Illinois-based Abbott is planning to appeal.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News